Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14671190 | 0.80 | KDM4E (0.39) | ALOX15ALDH1A1 | |
| SCHEMBL4902310 | 0.79 | TACR1 (0.40) | NPC1ARHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL9577039 | 0.78 | KCNA3 (0.43) | RAB9AKCNA3ALDH1A1 | |
| SCHEMBL15538067 | 0.76 | KDM4E (0.39) | ALOX15ALDH1A1 | |
| SCHEMBL2350595 | 0.75 | PPARD (0.45) | KMT2AARALDH1A1 | |
| SCHEMBL2591925 | 0.74 | KDM4E (0.37) | ALOX15ALDH1A1 | |
| SCHEMBL4207677 | 0.74 | ALDH1A1 (0.44) | MEN1KMT2AALOX15KCNA3ALDH1A1 | |
| SCHEMBL4210725 | 0.74 | TAAR1 (0.44) | KCNA3ALDH1A1 | |
| SCHEMBL9370329 | 0.73 | DPP4 (0.44) | MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9281344 | 0.73 | TACR1 (0.42) | MEN1KMT2ANPC1ARHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131502-A1 | Biologically active compounds | QUIBELL MARTIN | 2009-05-21 | — | — | US | disclosed |
| US-20090131502-A1 | Biologically active compounds | QUIBELL MARTIN | 2009-05-21 | — | — | US | disclosed |
| WO-2007023281-A2 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131502-A1 | Biologically active compounds | COLGALT1, SOST, COL1A1 | F2 1413/4885MEN1 185/4885HTT 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.